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In this report, we document for the first time the oc-
currence of D-tryptophan in a normally translated
polypeptide, contryphan. The peptide, isolated from the
venom of the fish-hunting marine snail Conus radiatus,
produces the “stiff-tail” syndrome in mice. Character-




where Hyp 5 4-trans-hydroxyproline.
The presence of D-tryptophan in position 4 of contry-
phan was confirmed by chemical synthesis. The post-
translational epimerization in all other D-amino acid-
containing small peptides characterized previously
from vertebrates and molluscan systems is in position 2.
The standard amino acids in polypeptides translated from
genes are exclusively in the L-configuration. In recent years it
has been established that D-amino acids can be post-transla-
tionally introduced into such polypeptides (1). Several small
peptides have been characterized, which contain a D-amino
acid. The first of these was dermorphin, a potent heptapeptide
agonist of the m-opiate receptor from amphibian skin, discov-
ered by Erspamer and co-workers (2). A number of other pep-
tides from amphibian skin (including the deltorphins and bom-
binin-H) were also found to have a D-amino acid. The cDNAs
encoding these peptides were characterized (3, 4). The results
demonstrated unequivocally the presence of mRNA encoding
the peptide precursor, indicating that the D-amino acid was
post-translationally formed from the corresponding L-isomer.
In addition to these vertebrate systems, small peptides with
D-amino acids have also been described in invertebrate sys-
tems, primarily molluscs. An FMRFamide analog from the
bivalve, Mytilus edulis, which contains a D-leucine, has been
characterized (5). Likewise, the land snail Achatina fulica has
D-amino acid-containing small peptides, achatin-I and fulicin
(6, 7). The cDNA encoding the precursor of fulicin was found to
contain the usual L-Asn codon at the D-Asn position (8). Re-
cently, the post-translational inversion of an amino acid was
demonstrated in vitro for v-agatoxin-IVB (also termed v-aga-
toxin-TK), a calcium channel inhibitor from funnel web spider
(9). The peptide isomerase that preferentially acts on Ser46 of
the 48-amino acid peptide has been isolated and characterized.
The small peptides which appear to be post-translationally
modified to convert an L- to a D-amino acid from a variety of
phylogenetic systems are shown in Table I. Although there is
no homology between vertebrate and invertebrate peptides
(and the three molluscan peptides exhibit no sequence similar-
ity), in every case the D-amino acid is found in the second
position. This suggests that for small D-amino acid-containing
peptides, the proteolytic event that generates the mature pep-
tide and the post-translational enzymatic system that converts
an L- to a D-amino acid work in combination to always generate
the D-amino acid at position 2.
In this report, we describe the purification and characteriza-
tion of a novel D-amino acid-containing peptide from the venom
of Conus radiatus, which causes a “stiff-tail syndrome” in mice.
This octapeptide, contryphan, has a D-tryptophan residue. This
is the first report of D-tryptophan being formed through post-
translational modification. Furthermore, in contrast to all of
the small D-amino acid-containing peptides shown in Table I,
contryphan does not have the D-amino acid in position 2. Like
most peptides found in Conus venoms, contryphan is cross-
linked by a disulfide bond; all other peptides in Table I are not
disulfide-crosslinked. The discovery and characterization of
contryphan indicates that the modification system for convert-
ing L- to D-amino acids evolved in Conus venom ducts differs
significantly from the post-translational isomerization of an L-
to a D-amino acid described previously for all other small pep-
tides in both vertebrate and previously characterized mollus-
can systems.
MATERIALS AND METHODS
Preparation of Venom Extract—Specimens of C. radiatus were ob-
tained from the Philippines. The venom ducts were dissected from the
cone snails, and the venom was squeezed out of the ducts as described
previously (10). The collected venom was lyophilized and stored in the
freezer. Five-hundred milligrams of lyophilized venom was sequentially
extracted with 10 ml each of water, 20% acetonitrile, 40% acetonitrile,
and 60% acetonitrile. The venom suspension was sonicated in the
extracting solvent for three 30-s periods over ice water and centrifuged
at 5000 3 g for 5 min. The combined supernatants were stored at
220 °C for further purification.
Purification of Peptides—Crude venom extract was applied onto a
Vydac C18 semi-preparative column (10 3 250 mm) and eluted with a
linear gradient of acetonitrile in 0.085% trifluoroacetic acid at 5 ml/min.
Further purifications of bioactive peaks were done on a Vydac C18
analytical column (4.6 3 250 mm) eluted with the acetonitrile/trifluoro-
acetic acid system at 1 ml/min. The effluents were monitored at 220 nm.
Peaks were collected in polypropylene tubes and aliquots were assayed
for biological activity.
Bioassay—Biological activity was assayed by intracranial injection
in mice (9–21 days old). Aliquots (20–30 ml) of peptide in normal saline
were injected using a 0.3 ml syringe with a 29-gauge needle. Each
control mouse was injected with an equal volume of normal saline
solution containing dissolved residue of lyophilized column buffer. After
injection, the mice were placed in cages for observation.
Peptide Sequencing—The peptide was reduced and alkylated prior to
sequencing. The pH of the peptide solution was raised to 7–8 by adding
0.5 M Tris base before dithiothreitol was added to a final concentration
of 10 mM. The solution was flushed with nitrogen, incubated at 65 °C for
20 min, and cooled to room temperature. Three microliters of 4-vi-
nylpyridine were added per 500 ml of solution. The mixture was left in
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the dark for 25 min at room temperature then diluted with 0.1%
trifluoroacetic acid and applied onto a Vydac C18 analytical HPLC
1
column.
The purified peptide was sequenced by automated Edman degrada-
tion (11) on an Applied Biosystems 477A protein sequencer with a 120A
analyzer (DNA/Peptide Facility, University of Utah). The 3-phenyl-2-
thiohydantoin derivatives were identified by HPLC. The predicted mass
of the peptide was compared with the molecular masses obtained by Dr.
Anthony Craig of the Salk Institute for Biological Studies using laser
desorption mass spectrometry and liquid secondary ionization mass
spectrometry (LSIMS). The LSIMS samples were measured at 3000
resolution from a glycerol matrix.
Peptide Synthesis—The protected peptide resin was synthesized us-
ing standard Fmoc (N-(9-fluorenyl)methoxycarbonyl) chemistry and
couplings using equimolar amounts of amino acid derivatives dicyclo-
hexylcarbodiimide and hydroxybenzotriazole. Some amino acid side
chains were protected as follows: Cys (trityl), OH-Pro (t-butyl), and Glu
(t-butyl).
After synthesis, the terminal Fmoc group was removed by treatment
with 1:4 piperidine:N-methylpyrrolidone (v/v). The peptide was cleaved
from the resin by treatment with trifluoroacetic acid/H20/ethanedithiol/
phenol/thioanisole (80/5/2.5/7.5/5 by volume) for 1.5 h at room temper-
ature. The mixture was filtered under vacuum into t-butyl methyl ether
at 210 °C. Linear peptide was collected by centrifugation at 5000 3 g
for 5 min and washed with t-butylmethyl ether. The pellet was dis-
solved in 20% acetonitrile containing 0.1% trifluoroacetic acid and ap-
plied into a Vydac C18 preparative column (25 3 250 mm). Elution was
carried out at 20 ml/min using a gradient of acetonitrile in 0.1% triflu-
oroacetic acid. The major peptide-containing fraction was oxidized with
1 mM iodine in 0.1% trifluoroacetic acid, 20% acetonitrile (12), then the
reaction was quenched with a few drops of 0.1 M ascorbic acid. The
oxidized peptide was purified by HPLC.
RESULTS
Purification of Contryphans—Crude venom was obtained
from specimens of C. radiatus collected from Manila Bay and
Marinduque. The crude venom extract prepared as described
under “Materials and Methods” was applied to a C18 semi-
preparative column, using a gradient of 0.45% CH3CN/min. A
complicated HPLC profile, typical of Conus venoms was ob-
tained (see Fig. 1A). When injected intracranially in mice,
material from the peaks indicated by the arrows caused mild
excitatory symptoms at low doses with tail raising and severe
symptoms including “barrel rolling” and seizure observed with
increasing dosages (see Table II).
The peak designated as R was resolved into several peaks on
HPLC in a C18 analytical column eluted with a very slow
gradient of acetonitrile. The first major peak, which showed the
same activity as the R peak of A was rechromatographed to give
a homogeneous peak shown in C. Similar HPLC runs of the R1
peak of A gave the profile in D; rechromatography of this peak
gave a homogeneous peptide.
Biochemical Characterization and Biological Activity of Con-
tryphan and Its Des-[Gly1] Derivative—The purified peptides
were reduced, alkylated, and sequenced as described under
“Materials and Methods.” The amino acid sequence obtained
for peak R is shown in Table III. Because of the high trypto-
phan content of this peptide, we designate it as “contryphan.”
Peptide R1 had an identical sequence except that it lacks the
NH2-terminal Gly residue. Thus, the amino acid sequences of
the two peptides are as follows.
Contryphan GCOWEPWC-NH2
Des-[Gly1]contryphan COWEPWC-NH2
Liquid secondary ionization mass spectrometry of the native
contryphan peptide gave a monoisotopic MH1 of 990.3 (calcu-
1 The abbreviations used are: HPLC, high performance liquid chro-
matography; ACN, acetonitrile; LSIMS, liquid secondary ionization
mass spectrometry.
TABLE I
Primary structure of small peptides containing D-amino acids
The underlined letters represent D-amino acid residues; * denotes COOH-terminal amide. All the rest are standard single letter codes for amino
acid residues. P. 5 Phyllomedusa; A. 5 Achatina; M. 5 Mytilus.
Peptide Sequence Source Phylum Ref.
Dermorphin YAFGYPS* P. sauvagei Vertebrata 2
Met-deltorphin YMFHLMD* P. sauvagei Vertebrata 20, 21
Achatin-I GFAD A. fulica Mollusca 6
Fulicin FNEFV* A. fulica Mollusca 7
Mytilus-FFRFamide ALAGDHFFRF* M. edulis Mollusca 5
FIG. 1. Purification of contryphan. A, HPLC chromatogram of C.
radiatus venom sequentially extracted with 10 ml each of H20 and 20%,
40%, and 60% ACN. Five milliliters of the combined extract from 500
mg of lyophilized venom was applied onto a C18 semi-preparative col-
umn and eluted at 5 ml/min using a linear gradient of ACN in 0.085%
trifluoroacetic acid (0.45% rise in ACN/min). The peaks corresponding
to contryphan (R) and des-[Gly1]contryphan (R1) are indicated by ar-
rows. B, HPLC chromatogram showing the purification of contryphan.
The bioactive fraction obtained from HPLC of crude venom extract was
applied onto a C18 analytical column and eluted at 1 ml/min using a
linear gradient of ACN in 0.085% trifluoroacetic acid (0.09% rise in
ACN/min). C, the peak was repurified at 1 ml/min with a gradient of
0.9% rise in ACN/min. D, HPLC chromatogram showing the purifica-
tion of des-[Gly1]contryphan. The bioactive fraction obtained from an
HPLC of crude venom extract was applied into C18 analytical column at
1 ml/min using a linear gradient of ACN in 0.085% trifluoroacetic acid
(0.09% rise in ACN/min). E, the peak indicated by the arrow in D was
repurified at 1 ml/min at a gradient of 0.9% rise in ACN/min.
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lated MH1 5 990.4) and a monoisotopic MH1 of 933.3 (calcu-
lated MH1 5 933.3) for des-[Gly1]contryphan. These values are
consistent with the amino acid sequences assigned with the
Cys residues present as disulfides and the COOH termini as
amide groups.
To independently verify the sequence, synthetic peptides
containing standard L-amino acids were prepared as described
under “Materials and Methods.” However, the synthetic pep-
tides did not co-elute with native contryphan. The all-L analog
of contryphan showed an unusually broad HPLC peak, and it
appeared to be less stable than the native peptide; flushing the
synthetic peptide solution with nitrogen seemed to retard its
degradation to a purple derivative. Because of the identical
mass of the native and synthetic L-amino acid-containing pep-
tide, synthetic peptide homologs containing D-tryptophan at
positions 4 and 7 of contryphan were synthesized. Both the
fully reduced and the oxidized/folded forms of the synthetic
D-Trp4 peptide co-eluted with the corresponding forms of the
natural peptide (see Fig. 2). The D-Trp4,7 and D-Trp7 analogs
did not co-elute with native contryphan (Fig. 3). The presence
of D-tryptophan in position 3 of des-[Gly1]contryphan was also
confirmed by chemical synthesis and co-elution of native and
synthetic material.
On intracranial injection into mice, synthetic contryphan
elicited identical symptomatology to the native material (tail
raising and hyperactivity) at low doses. Surprisingly, the all-L
analog, [L-Trp4]contryphan shows a similar activity, whereas
[D-Trp7]contryphan elicited no detectable activity (.10 nmol/g
body weight). Des-[Gly1]contryphan elicited similar symptoms
to contryphan but appears to be less potent; even at the highest
doses (20 nmol/g), the peptide did not cause any lethality.
DISCUSSION
The data presented above document the purification, char-
acterization, and chemical synthesis of two homologous pep-
tides, contryphan and des-[Gly1]contryphan from the venom of
Conus radiatus. The most striking feature of these peptides is
the presence of D-tryptophan, the first occurrence of this un-
usual amino acid in a Conus peptide. Indeed, as far as we are
aware, D-tryptophan has not been described previously in any
mRNA-encoded polypeptidic structure. Analysis of a cDNA
clone from a C. radiatus venom duct library encoding contry-
phan has shown that D-Trp is coded for by the standard codon
for L-Trp.2 Previous reports of the occurrence of D-tryptophan
are in peptide-like structures, which are almost certainly not
translated through the normal ribosomal route, such as in the
fungal aselacins, which are cyclic pentapeptolides (13).
In recent years it has been demonstrated that D-amino acids
can be introduced into small peptides through post-transla-
tional modification (1). The sequences of D-amino acid-contain-
ing small peptides is shown in Table I. Contryphan is distinct
from D-amino acid-containing peptides previously character-
ized in several respects. It appears to be the only small peptide
(#10 amino acids) containing a D-amino acid residue, which is
also disulfide-crosslinked. Furthermore, in other small pep-
tides, although a variety of different D-amino acids have been
found (including alanine, asparagine, methionine, phenylala-
nine, and leucine), the D-amino acid is always the penultimate
NH2-terminal amino acid (Table I). It has been suggested that
the isomerase for the Leu 3 Asp amino acid conversion may
cue into the dibasic signal for proteolytic processing of peptide
precursors (1), post-translationally converting the second
amino acid into the D-configuration regardless of the identity of
the amino acid at the designated locus. For contryphan the
number 2 position rule could not apply, since the D-amino acid
2 M. Watkins, E. C. Jimene´z, and D. R. Hillyard, unpublished results.
TABLE II
Bioactivity of contryphan
The dose ranges of contryphan shown were injected into mice as
described under “Materials and Methods.”
Dose Activity
Low: 0.5–2.5 nmol/g Grooming, licking and biting of paws, occasional
tail-raising, occasional hyperactivity.
Medium: 4–6 nmol/g Stiffening and raising of tail to almost
perpendicular to body; barrel-rolling, and
subsequent passivity.
High: 8–20 nmol/g Paralysis of extremities, circular motion, barrel-
rolling, seizure, and death.
TABLE III
Sequence analysis of contryphan
Sequence analysis and mass spectrometry were carried out as de-
scribed under “Materials and Methods.” Hyp 5 4-trans-hydroxyproline.
The calculated MH1 value assumes that the Cys residues form a disul-













MH1 observed: 990.3; MH1 calculated: 990.4
FIG. 2. HPLC co-elution of synthetic and naturally occurring
contryphan. Gradients are represented by dotted lines showing the
rise in percent of buffer B (90% ACN, 0.085% trifluoroacetic acid). A,
linear forms of synthetic peptide and contryphan reduced with dithio-
threitol (1.25% increase in buffer B/min). B, oxidized form of synthetic
peptide with native contryphan (1% increase in buffer B/min).
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Thus, although C. radiatus is a mollusc like Achatina or
Mytilus, the modification system in C. radiatus venom ducts for
the isomerization of Trp4 in contryphan must use a different
positional cue. It is relevant to note that in two arthropod
systems, very much larger polypeptides with D-amino acids
have been described, including a lobster neurohormone (14), as
well as the spider toxin v-agatoxin IVB (15, 16). In both of
these systems, the D-amino acid is not found in position 2. For
v-agatoxin IVB, which comprises 48 amino acids, the conver-
sion of Ser46 to the D-isomer has been found to enhance toxin
stability as well as potency as a calcium channel blocker (15,
17). In this case, an isomerase shown to be homologous to
serine proteases has been purified from the spider venom
ducts, which carries out the Leu 3 Asp conversion (9, 18). It
will be of interest to compare the contryphan modification
system with the spider enzyme and the enzymes carrying out
the fixed positional modification found in the small molluscan
and frog skin peptides. In contryphan, pairs of proline and
tryptophan residues are present, but only the more NH2-ter-
minal amino acid residues are post-translationally modified
(proline to hydroxyproline and L-tryptophan to D-tryptophan).
The more COOH-terminal residue remains unmodified in each
case. These results suggest that such modification enzymes
distinguish between closely apposed residues.
The discovery of contryphan raises the question of whether
other peptides with amino acids that have been post-transla-
tionally modified to the D-configuration exist in Conus venoms.
We should note that since no homolog with L-tryptophan was
found in C. radiatus venom, indicating that it is either absent
or present at much lower levels than the D-Trp isomer. Prelim-
inary results suggest that contryphans are distributed more
widely in Conus venoms, homologous peptides have been found
in venom ducts collected from other Conus species.3 Thus, the
ability to post-translationally modify an L- to a D-amino acid
may be widespread in Conus, and additional D-amino acid-
containing peptides unrelated to contryphan could well be pres-
ent in Conus venoms.
When injected into the mouse central nervous system, con-
tryphan elicits characteristic symptoms such as the stiff-tail
syndrome (Table II). At higher doses, more generalized excita-
tory effects (i.e. barrel rolling and seizures) are induced. The
mechanistic basis for the symptomatology observed is pres-
ently unknown. Recently, we suggested that at least some of
the excitatory activities present in the venoms of fish-hunting
cone snails may act together to cause an excitotoxic shock
response in the prey (19), which leads to very rapid immobili-
zation of the fish prey. Given the excitatory effects of contry-
phan in the mammalian central nervous system, a possible
function for this peptide in the venom is to contribute to the
excitotoxic shock response.
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FIG. 3. Reverse-phase HPLC chromatograms of contryphan
and analogs. a, contryphan; b, [D-Trp7]contryphan; c, [L-Trp4,D-
Trp7]contryphan; d, [L-Trp4]contryphan. Peptides were applied to a C18
analytical column (Vydac, 218TP54, 4.6 x 250 mm) and eluted using a
linear gradient from 13.5 to 40.5% ACN in 0.08% trifluoroacetic acid.
Peaks are labeled with the apparent percent ACN at which elution
occurred, calculated from the elution time. The elution position of
contryphan relative to its analogs is indicated by the dotted line. Mixing
experiments (not shown) demonstrate that authentic contryphan is well
resolved from the all-L, D-Trp7, or L-Trp4,D-Trp7 homologs, but the three
homologs are not well resolved from each other under these elution
conditions.
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